A Phase 2 interventional study of PRO 140 350mg weekly subcutaneous (SC) injection. in HIV and Human Immunodeficiency Virus, sponsored by CytoDyn, Inc.. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-07.
Sponsored by CytoDyn, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is an extension of Protocol PRO 140_CD 01 to further evaluate the long-term suppression of HIV-1 replication following substitution of stable combination antiretroviral therapy with a PRO 140 (Monoclonal CCR5 antibody) monotherapy in adult subjects with HIV-1 infection
This study is a Phase 2b, multi-center, extension study designed to evaluate the long-term efficacy, safety, and tolerability of PRO 140 monotherapy for the maintenance of viral suppression in patients who were stable on combination antiretroviral therapy and completed 12 weeks of treatment under PRO 140_CD 01 Treatment Substitution Study without experiencing virologic failure.
Consenting patients will continue to receive PRO 140 monotherapy until investigational product (IP) receives marketing approval or investigational new drug (IND) is withdrawn by Sponsor. There is one week overlap of existing retroviral regimen and PRO 140 at the end of the treatment extension phase in subjects who do not experience virologic failure.
PRO 140 will be administered as a 350 mg subcutaneous injection weekly during treatment extension phase. Study participants will be monitored for viral rebound on a weekly basis following initiation of PRO 140 monotherapy and will re-initiate their previous antiretroviral regimen if plasma HIV-1 RNA levels rise above 400 copies/ml on two consecutive blood draws at least 3 days apart.
.
3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.
This study's enrollment of 20 is below the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.
Browse Acquired Immunodeficiency Syndrome studies →CytoDyn, Inc. is the lead sponsor of 24 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 12 (100%) have results posted.
Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PRO 140 350mg weekly subcutaneous (SC) injection.
Drug: PRO 140 350mg weekly subcutaneous (SC) injection.
CCR5 Antagonist
Also known as: PRO 140
Time to Virologic Failure After Initiating PRO 140 Monotherapy
Virologic failure (VF) is defined as two consecutive HIV-1 RNA levels of ≥ 400 copies/ml separated by at least 3 days. The time to VF will be compared to a historical data (i.e., time to HIV-1 RNA viral load \> 500 copies/mL of 29 days). The statistical comparison will be conducted using Wilcoxon rank sum test and the median time to Virologic Failure for this study will be compared to 30 days.
Time frame: From treatment extension visit 1 (TE1) until virologic failure, assessed up to 125 weeks.
Proportion of Participants With Virologic Failure After Initiating PRO 140 Monotherapy.
Virologic failure is defined as two consecutive HIV-1 RNA levels of ≥ 400 copies/ml separated by at least 3 days.
Time frame: From treatment extension visit 1 (TE1) until virologic failure, assessed up to 125 weeks.
Mean Change in Viral Load (HIV-1 RNA Levels)
Mean change from baseline of HIV-1 RNA levels was assessed for each week during the treatment phase up until week 58. Weighted mean change in viral load (HIV-1 RNA levels) were calculated from baseline to week 58.
Time frame: From treatment extension visit TE2 (defined as baseline), until week 58 of extension treatment.
Mean Change in CD4 Cell Count
Mean change in CD4 cell count from baseline (TE2 visit) was assessed for each week during the treatment phase up until week 58. The average mean change was calculated from baseline to week 58.
Time frame: From treatment extension visit TE2 (defined as baseline), until week 58 of extension treatment.
Change in Quality of Life Metrics (up to TE107)
A Quality of Life (QoL) assessment using ACTG SF-21 was planned to be performed at screening visit (SV1), once every four weeks from treatment visit 4 (TE4) through treatment visit 107 (TE107), and at end of treatment (EOT). The ACTG SF-21 has 8 QoL domains with a standard score ranging from 0 (worst) to 100 (best).
Time frame: From TE4 (baseline) through every fourth weekly visits to treatment visit 107 (TE107) or EOT, up to 125 weeks.
Tolerability of Repeated Subcutaneous Administration of PRO 140 as Assessed by Study Participants(Using Visual Analogue Scale) and by Investigator-evaluation of Injection Site Reactions.
Tolerability of repeated subcutaneous administration of PRO 140 was planned to be assessed by the study participants using a Visual Analogue Scale, and by investigator-evaluation of injection site reactions. Injection site reaction assessment was not completed when subjects performed self-administration.
Time frame: From TE1 (first treatment administration) weekly until last treatment visit (up to 125 weeks)
Number of Participants With Grade 3 or 4 Adverse Events as Defined by the DAIDS Adverse Event Scale
The Division of AIDS (DAIDS) grading table provides an adverse event severity grading scale ranging from grades 1 to 5 with descriptions for each adverse event based on the following general guidelines: * Grade 1 indicates a mild event * Grade 2 indicates a moderate event * Grade 3 indicates a severe event * Grade 4 indicates a potentially life-threatening event * Grade 5 indicates death (Note: This grade is not specifically listed on each page of the grading table).
Time frame: From the first treatment visit (TE1) until final study visit, up to a 125 weeks.
Number of Participants With at Least One Treatment-related Serious Adverse Event.
Treatment-related serious adverse events are defined as serious events with an onset on or after the first treatment. A serious adverse event is defined as any adverse event that: * Results in death * Is life threatening (the subject is at immediate risk of dying from the AE) * Requires subject hospitalization or prolongs existing hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered a serious adverse event when, based upon appropriate medical judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.
Time frame: From the first treatment visit (TE1) until final study visit up to 125 weeks.
| Milestone | PRO 140 |
|---|---|
| Started | 20 |
| Completed | 8 |
| Not completed | 12 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Study terminated | 10 |
Virologic failure (VF) is defined as two consecutive HIV-1 RNA levels of ≥ 400 copies/ml separated by at least 3 days. The time to VF will be compared to a historical data (i.e., time to HIV-1 RNA viral load \> 500 copies/mL of 29 days). The statistical comparison will be conducted using Wilcoxon rank sum test and the median time to Virologic Failure for this study will be compared to 30 days.
| days | PRO 140 |
|---|---|
| Time to Virologic Failure After Initiating PRO 140 Monotherapy | 228.8 ± 225.6 |
Virologic failure is defined as two consecutive HIV-1 RNA levels of ≥ 400 copies/ml separated by at least 3 days.
| proportion of participants | PRO 140 |
|---|---|
| Proportion of Participants With Virologic Failure After Initiating PRO 140 Monotherapy. | 0.3 |
Mean change from baseline of HIV-1 RNA levels was assessed for each week during the treatment phase up until week 58. Weighted mean change in viral load (HIV-1 RNA levels) were calculated from baseline to week 58.
| copies/mL | PRO 140 |
|---|---|
| Mean Change in Viral Load (HIV-1 RNA Levels) | 147.34 ± 263.60 |
Mean change in CD4 cell count from baseline (TE2 visit) was assessed for each week during the treatment phase up until week 58. The average mean change was calculated from baseline to week 58.
| cells/uL | PRO 140 |
|---|---|
| Mean Change in CD4 Cell Count | 22 ± 111 |
A Quality of Life (QoL) assessment using ACTG SF-21 was planned to be performed at screening visit (SV1), once every four weeks from treatment visit 4 (TE4) through treatment visit 107 (TE107), and at end of treatment (EOT). The ACTG SF-21 has 8 QoL domains with a standard score ranging from 0 (worst) to 100 (best).
| score | PRO 140 |
|---|---|
| Change in Quality of Life Metrics (up to TE107) | 1.4 ± 5.9 |
Tolerability of repeated subcutaneous administration of PRO 140 was planned to be assessed by the study participants using a Visual Analogue Scale, and by investigator-evaluation of injection site reactions. Injection site reaction assessment was not completed when subjects performed self-administration.
No measurements were reported for this outcome.
The Division of AIDS (DAIDS) grading table provides an adverse event severity grading scale ranging from grades 1 to 5 with descriptions for each adverse event based on the following general guidelines: * Grade 1 indicates a mild event * Grade 2 indicates a moderate event * Grade 3 indicates a severe event * Grade 4 indicates a potentially life-threatening event * Grade 5 indicates death (Note: This grade is not specifically listed on each page of the grading table).
| Participants | PRO 140 |
|---|---|
| Number of Participants With Grade 3 or 4 Adverse Events as Defined by the DAIDS Adverse Event Scale | 7 |
Treatment-related serious adverse events are defined as serious events with an onset on or after the first treatment. A serious adverse event is defined as any adverse event that: * Results in death * Is life threatening (the subject is at immediate risk of dying from the AE) * Requires subject hospitalization or prolongs existing hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered a serious adverse event when, based upon appropriate medical judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.
| Participants | PRO 140 |
|---|---|
| Number of Participants With at Least One Treatment-related Serious Adverse Event. | 0 |
Collected over Adverse events were reported from the time of the first treatment and continued up until the final study visit to evaluate safety of PRO140 (up to a maximum of 91 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PRO 140 | 0/20 (0%) | 4/20 (20%) | 15/20 (75%) |
| Event | PRO 140 |
|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/20 |
| Intestinal PerforationGastrointestinal disorders | 1/20 |
| Suicide AttemptPsychiatric disorders | 1/20 |
| SyncopeNervous system disorders | 1/20 |
| HypertensionVascular disorders | 1/20 |
| Chest PainGeneral disorders | 1/20 |
| Bile duct stoneHepatobiliary disorders | 1/20 |
| Event | PRO 140 |
|---|---|
| NasopharyngitisInfections and infestations | 5/20 |
| Upper respiratory tract infectionInfections and infestations | 5/20 |
| DiarrhoeaGastrointestinal disorders | 4/20 |
| SinusitisInfections and infestations | 4/20 |
| InfluenzaInfections and infestations | 3/20 |
| GastroenteritisInfections and infestations | 3/20 |
| LymphadenopathyBlood and lymphatic system disorders | 3/20 |
| BronchitisInfections and infestations | 2/20 |
| Fungal skin infectionInfections and infestations | 2/20 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 2/20 |
Subjects with HIV-1 infection who did not experience virologic failure while in the treatment phase of the PRO 140\_CD 01 study.
| Age, Continuous(years) | PRO 140 |
|---|---|
| Mean | 56.05 (32 to 72) |
| Sex: Female, Male(Participants) | PRO 140 |
|---|---|
| Female | 2 |
| Male | 18 |
| Race (NIH/OMB)(Participants) | PRO 140 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 16 |
| More than one race | 0 |
| Unknown or Not Reported | 2 |
| Region of Enrollment(participants) | PRO 140 |
|---|---|
| United States | 20 |
| Time since HIV Diagnosis(years) | PRO 140 |
|---|---|
| Mean | 10 (2 to 37) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2014 to primary completion in Jun 2022, 91 months.
Results were first posted in Oct 2025, 3 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Leronlimab
Acquired Immunodeficiency Syndrome →